The Effects of C. lacerata on Insulin Resistance in Type 2 Diabetes Patients

Figure 2

Subgroup analysis on the changes in (a) HOMA-IR, (b) QUICKI, (c) fasting c-peptide (F.C-pep), and (d) fasting plasma insulin (F.PI) between the placebo and C. lacerata groups after 12 weeks of intervention according to HOMA-IR.

(a)

(b)

(c)

(d)